Highlights on hypertension at the JESFC 2014
Sebastian Ewen asks questions to Bernard Waeber, co-author of Assessment of drug compliance in patients with high blood pressure resistant to antihypertensive therapy, article published in EuroIntervention Journal Supplement on Resistant Hypertension Treatments, May 2013.
Please share with us your comments about this renal denervation case, opening the path...
Discuss about the perspective of transradial denervation while following this case.
In light of Medtronic’s announcement of Thursday, 9th January 2014, about SYMPLICITY HTN-3, the Resistant Hypertension Course Scientific Board shares its point of view.
Medtronic, Inc. announced yesterday that its U.S. trial in renal denervation for treatment-resistant hypertension, SYMPLICITY HTN-3, has met its primary safety endpoint, while it did not reach its primary efficacy endpoint, defined as a difference of, at least, 15 mmHg office systolic blood pressure, between sham and active renal denervation groups.
The RHC Board shares its point of view:
In light of Medtronic’s announcement of Thursday, 9th January 2014, about SYMPLICITY HTN-3...
- Why come to RHC 2014 in Berlin, next February?
- Why is a pharmacology-oriented session important for the participants?
In these three case-based presentations you can learn how to:
- conduct a personalized, step-by-step assessment of a patient presenting with "uncontrolled hypertension"
- better understand what information is key to rule out all spurious resistant hypertension causes